{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:25:57Z","timestamp":1775067957971,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3\/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel]) in healthy adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seven clinical drug\u2013drug interaction studies were analysed. Pharmacokinetic parameters for drugs as measured in blood plasma were used to estimate the drug interaction potential with ritlecitinib as a perpetrator or victim.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Midazolam exposure (area under plasma concentration\u2013time curve from time 0 to infinity [AUC<jats:sub>inf<\/jats:sub>]) and peak exposure (maximum concentration [C<jats:sub>max<\/jats:sub>]) were increased by \u2248169% and \u224880.1%, respectively, in the presence of ritlecitinib. Efavirenz exposure (AUC<jats:sub>0\u201372<\/jats:sub>) and peak exposure (C<jats:sub>max<\/jats:sub>) were similar in the presence and absence of ritlecitinib coadministration. Tolbutamide pharmacokinetic parameters (AUC<jats:sub>inf<\/jats:sub> and C<jats:sub>max<\/jats:sub>) were not affected by multiple ritlecitinib doses. In the presence of ritlecitinib, AUC<jats:sub>inf<\/jats:sub> and C<jats:sub>max<\/jats:sub> of caffeine increased by \u2248165% and \u224810%, respectively. AUC<jats:sub>inf<\/jats:sub> and C<jats:sub>max<\/jats:sub> of ethinyl oestradiol decreased by \u224818% and \u224812%, respectively, following coadministration of multiple ritlecitinib 200 mg once\u2010daily doses, but no relevant change was observed following multiple 50\u2009mg once\u2010daily doses. Ritlecitinib doses did not affect the pharmacokinetics of levonorgestrel. Coadministration following multiple itraconazole doses increased ritlecitinib AUC<jats:sub>inf<\/jats:sub> by \u224815%. Coadministration following multiple rifampicin doses decreased AUC<jats:sub>inf<\/jats:sub> of ritlecitinib by \u224845%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ritlecitinib is a moderate inhibitor of CYP3A and CYP1A2. Strong CYP inducers can reduce ritlecitinib concentrations, but not to clinically relevant levels leading to lack of benefit.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bcp.70069","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:33:11Z","timestamp":1746599591000},"page":"2316-2326","source":"Crossref","is-referenced-by-count":2,"title":["Drug\u2013drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450"],"prefix":"10.1002","volume":"91","author":[{"given":"Vivek S.","family":"Purohit","sequence":"first","affiliation":[{"name":"Pfizer Inc  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeamin","family":"Huh","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Plotka","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hindu","family":"Kalluru","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Private Ltd  Chennai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hee","sequence":"additional","affiliation":[{"name":"Pfizer Inc  La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Clinical drug interaction studies \u2010 cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions: guidance for industry","author":"Research USDoHaHSFaDACfDEa"},{"key":"e_1_2_10_3_1","unstructured":"Agency EM.Guideline on the investigation of drug interactions.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2023129"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.008"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.167"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.015"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.042"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxab002"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_2_10_12_1","unstructured":"FDA Approves Pfizer's LITFULO\u2122 (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata2023.https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and"},{"key":"e_1_2_10_13_1","unstructured":"Agency EM.Litfulo (ritlecitinib).https:\/\/www.ema.europa.eu\/en\/documents\/overview\/litfulo-epar-medicine-overview_en.pdf"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.013"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15695"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2215"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.1c00161"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.031393"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010022\u201003393\u20100"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200221999210101233135"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010013\u20100117\u20106"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666141125121511"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200342090\u201000003"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010013\u20100115\u20100"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318\u2010024\u201000893\u20105"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100072"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00222\u20102"},{"key":"e_1_2_10_28_1","volume-title":"Litfulo (ritlecitinib) [prescribing information]","year":"2023"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.5546\/aap.2017.eng.e404"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010023\u201001318\u20103"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3102"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12981"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824999180115103951"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200038010\u201000003"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2057323"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010022\u201001200\u20104"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.956"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199937050\u201000003"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12050823"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:15:34Z","timestamp":1753773334000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/bcp.70069"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70069","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}